APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Osteoarthritis Pain

Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.

Selected research

Market Analysis & Forecast

Global Drugs for Osteoarthritis Pain Market Analysis and Forecast 2026-2032

22 December 2025201 pages

Choose your research edition.

Industry ResearchDrugs for Osteoarthritis Pain Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Osteoarthritis Pain Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Drugs for Osteoarthritis Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Osteoarthritis Pain Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.

North America is the largest Drugs for Osteoarthritis Pain market with about 36% market share. Europe is follower, accounting for about 27% market share.

The key players are Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma etc. Top 5 companies occupied about 66% market share.

Read the full market overview

Report Includes

This report presents an overview of global market for Drugs for Osteoarthritis Pain, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Osteoarthritis Pain, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Osteoarthritis Pain, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Osteoarthritis Pain revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Osteoarthritis Pain market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Osteoarthritis Pain revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Osteoarthritis Pain Segment by Company

Pfizer

Johnson & Johnson

GlaxoSmithKline

Bayer

Eli Lilly

Novartis

Sanofi

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Abiogen Pharma

Drugs for Osteoarthritis Pain Segment by Type

Oral

Injection

External

Drugs for Osteoarthritis Pain Segment by Application

Medical Care

Personal Care

Drugs for Osteoarthritis Pain Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Osteoarthritis Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Osteoarthritis Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Osteoarthritis Pain.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Osteoarthritis Pain in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Osteoarthritis Pain company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Osteoarthritis Pain revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Osteoarthritis Pain Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Injection Major Player Table 4. External Major Player Table 5. Global Drugs for Osteoarthritis Pain Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Medical Care Major Player Table 7. Personal Care Major Player Table 8. Drugs for Osteoarthritis Pain Industry Trends Table 9. Drugs for Osteoarthritis Pain Industry Drivers Table 10. Drugs for Osteoarthritis Pain Industry Opportunities and Challenges Table 11. Drugs for Osteoarthritis Pain Industry Restraints Table 12. Global Drugs for Osteoarthritis Pain Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Drugs for Osteoarthritis Pain Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Drugs for Osteoarthritis Pain Market Share by Region (2021-2026) Table 15. Global Drugs for Osteoarthritis Pain Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Drugs for Osteoarthritis Pain Market Share by Region (2027-2032) Table 17. Global Drugs for Osteoarthritis Pain Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Drugs for Osteoarthritis Pain Revenue Market Share by Players (2021-2026) Table 19. Global Drugs for Osteoarthritis Pain Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Drugs for Osteoarthritis Pain Key Players Headquarters & Area Served Table 21. Global Drugs for Osteoarthritis Pain Players, Product Type & Application Table 22. Global Drugs for Osteoarthritis Pain Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Drugs for Osteoarthritis Pain by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Drugs for Osteoarthritis Pain Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Drugs for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Drugs for Osteoarthritis Pain Revenue Market Share by Type (2021-2026) Table 29. Global Drugs for Osteoarthritis Pain Revenue Market Share by Type (2027-2032) Table 30. Global Drugs for Osteoarthritis Pain Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Drugs for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Drugs for Osteoarthritis Pain Revenue Market Share by Application (2021-2026) Table 34. Global Drugs for Osteoarthritis Pain Revenue Market Share by Application (2027-2032) Table 35. Pfizer Company Information Table 36. Pfizer Business Overview Table 37. Pfizer Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Pfizer Drugs for Osteoarthritis Pain Product Portfolio Table 39. Pfizer Recent Development Table 40. Johnson & Johnson Company Information Table 41. Johnson & Johnson Business Overview Table 42. Johnson & Johnson Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson & Johnson Drugs for Osteoarthritis Pain Product Portfolio Table 44. Johnson & Johnson Recent Development Table 45. GlaxoSmithKline Company Information Table 46. GlaxoSmithKline Business Overview Table 47. GlaxoSmithKline Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. GlaxoSmithKline Drugs for Osteoarthritis Pain Product Portfolio Table 49. GlaxoSmithKline Recent Development Table 50. Bayer Company Information Table 51. Bayer Business Overview Table 52. Bayer Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bayer Drugs for Osteoarthritis Pain Product Portfolio Table 54. Bayer Recent Development Table 55. Eli Lilly Company Information Table 56. Eli Lilly Business Overview Table 57. Eli Lilly Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Eli Lilly Drugs for Osteoarthritis Pain Product Portfolio Table 59. Eli Lilly Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novartis Drugs for Osteoarthritis Pain Product Portfolio Table 64. Novartis Recent Development Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Sanofi Drugs for Osteoarthritis Pain Product Portfolio Table 69. Sanofi Recent Development Table 70. Horizon Pharma Company Information Table 71. Horizon Pharma Business Overview Table 72. Horizon Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Horizon Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 74. Horizon Pharma Recent Development Table 75. Abbott Company Information Table 76. Abbott Business Overview Table 77. Abbott Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Abbott Drugs for Osteoarthritis Pain Product Portfolio Table 79. Abbott Recent Development Table 80. Mylan Company Information Table 81. Mylan Business Overview Table 82. Mylan Drugs for Osteoarthritis Pain Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Mylan Drugs for Osteoarthritis Pain Product Portfolio Table 84. Mylan Recent Development Table 85. Daiichi Sankyo Company Information Table 86. Daiichi Sankyo Business Overview Table 87. Daiichi Sankyo Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 88. Daiichi Sankyo Drugs for Osteoarthritis Pain Product Portfolio Table 89. Daiichi Sankyo Recent Development Table 90. TEVA Company Information Table 91. TEVA Business Overview Table 92. TEVA Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 93. TEVA Drugs for Osteoarthritis Pain Product Portfolio Table 94. TEVA Recent Development Table 95. Almatica Pharma Company Information Table 96. Almatica Pharma Business Overview Table 97. Almatica Pharma Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 98. Almatica Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 99. Almatica Pharma Recent Development Table 100. Astellas Pharma Company Information Table 101. Astellas Pharma Business Overview Table 102. Astellas Pharma Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 103. Astellas Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 104. Astellas Pharma Recent Development Table 105. Tide Pharmaceutical Company Information Table 106. Tide Pharmaceutical Business Overview Table 107. Tide Pharmaceutical Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 108. Tide Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio Table 109. Tide Pharmaceutical Recent Development Table 110. Iroko Pharmaceuticals Company Information Table 111. Iroko Pharmaceuticals Business Overview Table 112. Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 113. Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Product Portfolio Table 114. Iroko Pharmaceuticals Recent Development Table 115. Hengrui Pharmaceutical Company Information Table 116. Hengrui Pharmaceutical Business Overview Table 117. Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 118. Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio Table 119. Hengrui Pharmaceutical Recent Development Table 120. Abiogen Pharma Company Information Table 121. Abiogen Pharma Business Overview Table 122. Abiogen Pharma Drugs for Osteoarthritis Pain Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 123. Abiogen Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 124. Abiogen Pharma Recent Development Table 125. North America Drugs for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 126. North America Drugs for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 127. North America Drugs for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 128. North America Drugs for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 129. North America Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. North America Drugs for Osteoarthritis Pain Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Drugs for Osteoarthritis Pain Revenue by Country (US$ Million) & (2027-2032) Table 132. Europe Drugs for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 133. Europe Drugs for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 134. Europe Drugs for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 135. Europe Drugs for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 136. Europe Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Europe Drugs for Osteoarthritis Pain Revenue by Country (2021-2026) & (US$ Million) Table 138. Europe Drugs for Osteoarthritis Pain Revenue by Country (US$ Million) & (2027-2032) Table 139. China Drugs for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 140. China Drugs for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 141. China Drugs for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 142. China Drugs for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 143. Asia Drugs for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 144. Asia Drugs for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 145. Asia Drugs for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 146. Asia Drugs for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 147. Asia Drugs for Osteoarthritis Pain Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Asia Drugs for Osteoarthritis Pain Revenue by Region (US$ Million) & (2021-2026) Table 149. Asia Drugs for Osteoarthritis Pain Revenue by Region (US$ Million) & (2027-2032) Table 150. SAMEA Drugs for Osteoarthritis Pain Revenue by Type (2021-2026) & (US$ Million) Table 151. SAMEA Drugs for Osteoarthritis Pain Revenue by Type (2027-2032) & (US$ Million) Table 152. SAMEA Drugs for Osteoarthritis Pain Revenue by Application (2021-2026) & (US$ Million) Table 153. SAMEA Drugs for Osteoarthritis Pain Revenue by Application (2027-2032) & (US$ Million) Table 154. SAMEA Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. SAMEA Drugs for Osteoarthritis Pain Revenue by Country (2021-2026) & (US$ Million) Table 156. SAMEA Drugs for Osteoarthritis Pain Revenue by Country (US$ Million) & (2027-2032) Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Drugs for Osteoarthritis Pain Image Figure 2. Global Drugs for Osteoarthritis Pain Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Osteoarthritis Pain Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. External Image Figure 7. Global Drugs for Osteoarthritis Pain Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs for Osteoarthritis Pain Market Size Share 2021 VS 2025 VS 2032 Figure 9. Medical Care Image Figure 10. Personal Care Image Figure 11. Global Drugs for Osteoarthritis Pain Market Size (US$ Million) & (2021-2032) Figure 12. Global Drugs for Osteoarthritis Pain Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Osteoarthritis Pain Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Osteoarthritis Pain Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Drugs for Osteoarthritis Pain Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for Osteoarthritis Pain Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Osteoarthritis Pain Revenue Market Share by Type (2021-2032) Figure 19. Global Drugs for Osteoarthritis Pain Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Drugs for Osteoarthritis Pain Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Drugs for Osteoarthritis Pain Revenue Market Share by Application (2021-2032) Figure 22. North America Drugs for Osteoarthritis Pain Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 24. North America Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 25. North America Drugs for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 26. United States Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Drugs for Osteoarthritis Pain Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 31. Europe Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 32. Europe Drugs for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 33. Germany Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Drugs for Osteoarthritis Pain Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 43. China Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 44. Asia Drugs for Osteoarthritis Pain Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 46. Asia Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 47. Asia Drugs for Osteoarthritis Pain Revenue Share by Region (2021-2032) Figure 48. Japan Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Drugs for Osteoarthritis Pain Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032) Figure 56. SAMEA Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032) Figure 57. SAMEA Drugs for Osteoarthritis Pain Revenue Share by Country (2021-2032) Figure 58. Brazil Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Drugs for Osteoarthritis Pain Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Johnson & Johnson
  • GlaxoSmithKline
  • Bayer
  • Eli Lilly
  • Novartis
  • Sanofi
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical
  • Abiogen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Osteoarthritis Pain Market by Type
  3. 1.2.1 Global Drugs for Osteoarthritis Pain Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.2.4 External
  7. 1.3 Drugs for Osteoarthritis Pain Market by Application
  8. 1.3.1 Global Drugs for Osteoarthritis Pain Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Medical Care
  10. 1.3.3 Personal Care
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Drugs for Osteoarthritis Pain Market Dynamics
  1. 2.1 Drugs for Osteoarthritis Pain Industry Trends
  2. 2.2 Drugs for Osteoarthritis Pain Industry Drivers
  3. 2.3 Drugs for Osteoarthritis Pain Industry Opportunities and Challenges
  4. 2.4 Drugs for Osteoarthritis Pain Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs for Osteoarthritis Pain Market Perspective (2021-2032)
  2. 3.2 Global Drugs for Osteoarthritis Pain Growth Trends by Region
  3. 3.2.1 Global Drugs for Osteoarthritis Pain Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Osteoarthritis Pain Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs for Osteoarthritis Pain Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs for Osteoarthritis Pain Revenue by Players
  2. 4.1.1 Global Drugs for Osteoarthritis Pain Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs for Osteoarthritis Pain Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs for Osteoarthritis Pain Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Osteoarthritis Pain Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs for Osteoarthritis Pain Key Players Headquarters & Area Served
  7. 4.4 Global Drugs for Osteoarthritis Pain Players, Product Type & Application
  8. 4.5 Global Drugs for Osteoarthritis Pain Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs for Osteoarthritis Pain Market CR5 and HHI
  11. 4.6.3 2025 Drugs for Osteoarthritis Pain Tier 1, Tier 2, and Tier 3
5 Drugs for Osteoarthritis Pain Market Size by Type
  1. 5.1 Global Drugs for Osteoarthritis Pain Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 5.3 Global Drugs for Osteoarthritis Pain Revenue Market Share by Type (2021-2032)
6 Drugs for Osteoarthritis Pain Market Size by Application
  1. 6.1 Global Drugs for Osteoarthritis Pain Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs for Osteoarthritis Pain Revenue by Application (2021-2032)
  3. 6.3 Global Drugs for Osteoarthritis Pain Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Drugs for Osteoarthritis Pain Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Drugs for Osteoarthritis Pain Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 GlaxoSmithKline
  14. 7.3.1 GlaxoSmithKline Company Information
  15. 7.3.2 GlaxoSmithKline Business Overview
  16. 7.3.3 GlaxoSmithKline Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Drugs for Osteoarthritis Pain Product Portfolio
  18. 7.3.5 GlaxoSmithKline Recent Developments
  19. 7.4 Bayer
  20. 7.4.1 Bayer Company Information
  21. 7.4.2 Bayer Business Overview
  22. 7.4.3 Bayer Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bayer Drugs for Osteoarthritis Pain Product Portfolio
  24. 7.4.5 Bayer Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly Drugs for Osteoarthritis Pain Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Drugs for Osteoarthritis Pain Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Sanofi
  38. 7.7.1 Sanofi Company Information
  39. 7.7.2 Sanofi Business Overview
  40. 7.7.3 Sanofi Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi Drugs for Osteoarthritis Pain Product Portfolio
  42. 7.7.5 Sanofi Recent Developments
  43. 7.8 Horizon Pharma
  44. 7.8.1 Horizon Pharma Company Information
  45. 7.8.2 Horizon Pharma Business Overview
  46. 7.8.3 Horizon Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Horizon Pharma Drugs for Osteoarthritis Pain Product Portfolio
  48. 7.8.5 Horizon Pharma Recent Developments
  49. 7.9 Abbott
  50. 7.9.1 Abbott Company Information
  51. 7.9.2 Abbott Business Overview
  52. 7.9.3 Abbott Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Abbott Drugs for Osteoarthritis Pain Product Portfolio
  54. 7.9.5 Abbott Recent Developments
  55. 7.10 Mylan
  56. 7.10.1 Mylan Company Information
  57. 7.10.2 Mylan Business Overview
  58. 7.10.3 Mylan Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Mylan Drugs for Osteoarthritis Pain Product Portfolio
  60. 7.10.5 Mylan Recent Developments
  61. 7.11 Daiichi Sankyo
  62. 7.11.1 Daiichi Sankyo Company Information
  63. 7.11.2 Daiichi Sankyo Business Overview
  64. 7.11.3 Daiichi Sankyo Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Daiichi Sankyo Drugs for Osteoarthritis Pain Product Portfolio
  66. 7.11.5 Daiichi Sankyo Recent Developments
  67. 7.12 TEVA
  68. 7.12.1 TEVA Company Information
  69. 7.12.2 TEVA Business Overview
  70. 7.12.3 TEVA Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  71. 7.12.4 TEVA Drugs for Osteoarthritis Pain Product Portfolio
  72. 7.12.5 TEVA Recent Developments
  73. 7.13 Almatica Pharma
  74. 7.13.1 Almatica Pharma Company Information
  75. 7.13.2 Almatica Pharma Business Overview
  76. 7.13.3 Almatica Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Almatica Pharma Drugs for Osteoarthritis Pain Product Portfolio
  78. 7.13.5 Almatica Pharma Recent Developments
  79. 7.14 Astellas Pharma
  80. 7.14.1 Astellas Pharma Company Information
  81. 7.14.2 Astellas Pharma Business Overview
  82. 7.14.3 Astellas Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Astellas Pharma Drugs for Osteoarthritis Pain Product Portfolio
  84. 7.14.5 Astellas Pharma Recent Developments
  85. 7.15 Tide Pharmaceutical
  86. 7.15.1 Tide Pharmaceutical Company Information
  87. 7.15.2 Tide Pharmaceutical Business Overview
  88. 7.15.3 Tide Pharmaceutical Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Tide Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio
  90. 7.15.5 Tide Pharmaceutical Recent Developments
  91. 7.16 Iroko Pharmaceuticals
  92. 7.16.1 Iroko Pharmaceuticals Company Information
  93. 7.16.2 Iroko Pharmaceuticals Business Overview
  94. 7.16.3 Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Product Portfolio
  96. 7.16.5 Iroko Pharmaceuticals Recent Developments
  97. 7.17 Hengrui Pharmaceutical
  98. 7.17.1 Hengrui Pharmaceutical Company Information
  99. 7.17.2 Hengrui Pharmaceutical Business Overview
  100. 7.17.3 Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio
  102. 7.17.5 Hengrui Pharmaceutical Recent Developments
  103. 7.18 Abiogen Pharma
  104. 7.18.1 Abiogen Pharma Company Information
  105. 7.18.2 Abiogen Pharma Business Overview
  106. 7.18.3 Abiogen Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Abiogen Pharma Drugs for Osteoarthritis Pain Product Portfolio
  108. 7.18.5 Abiogen Pharma Recent Developments
8 North America
  1. 8.1 North America Drugs for Osteoarthritis Pain Revenue (2021-2032)
  2. 8.2 North America Drugs for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs for Osteoarthritis Pain Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs for Osteoarthritis Pain Revenue by Type (2027-2032)
  5. 8.3 North America Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs for Osteoarthritis Pain Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs for Osteoarthritis Pain Revenue by Application (2027-2032)
  9. 8.5 North America Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs for Osteoarthritis Pain Revenue by Country
  11. 8.6.1 North America Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs for Osteoarthritis Pain Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs for Osteoarthritis Pain Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for Osteoarthritis Pain Revenue (2021-2032)
  2. 9.2 Europe Drugs for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs for Osteoarthritis Pain Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs for Osteoarthritis Pain Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs for Osteoarthritis Pain Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs for Osteoarthritis Pain Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs for Osteoarthritis Pain Revenue by Country
  11. 9.6.1 Europe Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs for Osteoarthritis Pain Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs for Osteoarthritis Pain Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drugs for Osteoarthritis Pain Revenue (2021-2032)
  2. 10.2 China Drugs for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs for Osteoarthritis Pain Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs for Osteoarthritis Pain Revenue by Type (2027-2032)
  5. 10.3 China Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs for Osteoarthritis Pain Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs for Osteoarthritis Pain Revenue by Application (2027-2032)
  9. 10.5 China Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Osteoarthritis Pain Revenue (2021-2032)
  2. 11.2 Asia Drugs for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs for Osteoarthritis Pain Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs for Osteoarthritis Pain Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs for Osteoarthritis Pain Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs for Osteoarthritis Pain Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs for Osteoarthritis Pain Revenue by Country
  11. 11.6.1 Asia Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs for Osteoarthritis Pain Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs for Osteoarthritis Pain Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Osteoarthritis Pain Revenue (2021-2032)
  2. 12.2 SAMEA Drugs for Osteoarthritis Pain Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs for Osteoarthritis Pain Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs for Osteoarthritis Pain Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs for Osteoarthritis Pain Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs for Osteoarthritis Pain Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs for Osteoarthritis Pain Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs for Osteoarthritis Pain Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs for Osteoarthritis Pain Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs for Osteoarthritis Pain Revenue by Country
  11. 12.6.1 SAMEA Drugs for Osteoarthritis Pain Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs for Osteoarthritis Pain Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs for Osteoarthritis Pain Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst